FDA 483 - Summit Biosciences Inc. - February 21, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Summit Biosciences Inc., a drug manufacturer in Lexington, KY, revealed two significant observations. The firm failed to implement adequate systems for Drug Supply Chain Security Act (DSCSA) verification, specifically regarding procedures for identifying and investigating suspect drug products. Additionally, the inspection found a lack of established written procedures for in-process controls, including validated 100% visual inspection and Accepted Quality Limit (AQL) inspection for particulate matter in their nasal drug products.
ID · f1c02c76-4a6d-4a2a-96f8-502730a91773